Condition category
Nutritional, Metabolic, Endocrine
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status

Plain English Summary

Background and study aims
This study will look at whether people who have recently had a heart attack and have a borderline underactive thyroid would benefit from being treated with levothyroxine for a year. It is not known whether taking levothyroxine may benefit heart function, make blood clots smaller and improve blood circulation or not.

Who can participate?
Adults aged between 18-75 years that have recently had a heart attack and have a borderline underactive thyroid.

What does the study involve?
Participants are randomly allocated into one of two groups. Those in group 1 are given levothyroxine. Those in group 2 are given a dummy medication (placebo). There are 11 visits over a year. These include a screening visit where questions are asked about the participants medical history, measure height, weight, blood pressure and pulse. Samples of blood are taken to look at thyroid function, cholesterol levels and circulation health. Subsequent visits involve Magnetic Resonance Imaging (MRI) cans of the heart, measuring stiffness of the blood vessels, clotting tests and further thyroid function tests. Each participant is asked about their general health and heart at the end of the study also asked to complete three questionnaires about their general health and heart. Their weight, blood pressure and pulse are taken once more and blood samples are taken to look at thyroid function, cholesterol levels and circulation health.

What are the possible benefits and risks of participating?
Any test may detect abnormalities that may be unrelated to the thyroid or heart condition – termed as incidental findings. In these cases, the participants GP will be informed. It is hoped that this study will provide valuable information about whether people with a borderline underactive thyroid who have recently had a heart attack would benefit from taking the correct dose of levothyroxine. The study may not directly benefit participants but they may benefit from a better understanding of borderline underactive thyroid gland and heart disease. The disadvantages for participants are that they will have blood samples taken more frequently than usual. They may get a small bruise, have discomfort or very rarely get an infection at the needle site. In addition the MRI scan can be noisy. Headphones are provided so that the participant can listen to music during the procedure. Some people may find the MRI scanner to be claustrophobic. Relaxation techniques can be advised if this happens. When participants attend for the clotting chamber test at the RVI they will need to have an overnight fast for 8 hours although water can be taken. If participants are taking painkillers called NSAIDs (such as ibuprofen and diclofenac) they will be asked to stop taking them at least 3 days before these visits.

Where is the study run from?
The Newcastle MR Centre at the Campus for Ageing and Vitality at Newcastle General Hospital or the Clinical Research Facility at the Royal Victoria Infirmary in Newcastle (UK).

When is the study starting and how long is it expected to run for?
December 2014 to April 2018

Who is funding the study?
National Institute of Health Research (UK)

Who is the main contact?
Miss Lorna Ingoe

Trial website

Contact information



Primary contact

Miss Lorna Ingoe


Contact details

Department of Diabetes and Endocrinology
Queen Elizabeth Hospital
Sheriff Hill
United Kingdom

Additional identifiers

EudraCT number

2014-001369-28 number

Protocol/serial number


Study information

Scientific title

ThyrAMI: Multi-centre double-blinded placebo-controlled RCT (cTIMP) of sub-clinical hypothyroid individuals post acute myocardial infarction



Study hypothesis

To determine whether treatment of sub clinical hypothyroidism with levothyroxine following acute myocardial infarction improves left ventricular function, thrombus area, endothelial function, health status, quality of life and is safe.

Ethics approval

Sunderland Research Ethics Service, 28/05/2014, ref: 14/NE/0151

Study design

Randomised; Interventional; Multicentre

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet


Topic: Metabolic and endocrine disorders; Subtopic: Metabolic and Endocrine (all Subtopics); Disease: Metabolic & Endocrine (not diabetes)


There are two arms on the study. One arm is the active study drug Levothyroxine and the second arm is the placebo control. Randomisation is 1:1.

Intervention type



Phase IV

Drug names


Primary outcome measure

The primary outcome measure will be change in left ventricular ejection fraction as assessed by magnetic resonance imaging. Cardiac magnetic resonance (MR) is considered the gold standard for evaluating cardiac volumes and function. Gradient echo sequences provide a naturally high level of contrast between intra-cavitary blood and myocardium, thus allowing an accurate and reproducible determination of LV volumes, mass and calculation of stroke volume and ejection fraction. In this context, additional information can also be drawn from application of the more recent cardiac MR tagging analysis, which represents a non-invasive highly accurate method for direct quantification of regional systolic function. Cardiac MR imaging will be performed at the dedicated 3T MRI centre in Newcastle University.

Secondary outcome measures

1. Left ventricular systolic and end diastolic volumes and myocardial viability: Cardiac MR parameters of both global and segmental LV function measurements will be obtained as per standardised protocols already in place in the Newcastle MR centre using a steady state free precession or fast gradient echo technique. In addition, further scans will be obtained 15-20 minutes after intra-venous gadolinium-chelate administration (delayed enhancement MRI). Regions of non-viable myocardial tissue will be identified as areas of increased enhancement (hyper enhancement) whereas viable tissue will have null (black) on the acquired images.
2. Thrombus burden: The Badimon chamber is a highly reproducible clinical ex vivo model of thrombosis that mimics flow conditions within the coronary circulation of man. The device incorporates two chambers with internal flow channels of different diameters, one simulating high-shear flow of 1690 ml/s and the other simulating low-shear flow. The internal flow channels are lined with porcine aortic tunica media - the thrombogenic substrate. After perfusion with venous blood from the patient, flowing at 10 mL min -1 for 5 min, aortic segments are fixed in 10% formalin for 72 h. Total thrombus burden is measured using a validated computer-assisted planimetry using IMAGE-PRO PLUS software (Media Cybernetics, Inc., Bethesda, MD, USA). The results are the mean of the analyzed sections (µm2 .mm-1). The measurements will be performed at the Clinical Research Facility (CRF), where they have considerable experience of using this technique in other high vascular risk groups.
3. Thromboelastography (TEG®): This is a non-invasive measure of evaluating efficiency and quality of ex vivo thrombus formation. Quantitative measures include clotting time parameters, clot strength and clot lysis. These parameters have been validated as highly correlated with longer term cardiac outcomes in several conditions of risk. TEG® will be measured at the CRF, RVI, Newcastle.
4. Endothelial function: Endothelial dysfunction is the earliest stage in the atherosclerosis disease process. In this study, endothelial function will be assessed by measuring peripheral arterial tone using a validated tool, EndoPAT®. Endothelial function assessment using EndoPAT® has been shown to have a high degree of correlation with coronary artery endothelial function (24), severity and extent of coronary artery disease, traditional cardiovascular risk factors and in predicting future cardiovascular events. EndoPAT® assessments will be performed at the Clinical Research Facility, RVI, Newcastle at baseline and at end of study.
5. Platelet reactivity: The reactivity (inhibition) of platelets to anti-platelet agents such as aspirin, clopidogrel, prasugrel and ticagrelor will be quantified by the point of care monitor VerifyNow® (Accumetrics, CA, USA). Arachidonic acid reactive units and P2Y12 reactive units will be recorded at baseline and at the end of the study. This test will not be carried out in individuals on anticoagulants such as warfarin.
6. Safety assessments: Safety of levothyroxine therapy in post AMI patients will be assessed at each study visit by enquiry of symptoms by New York Heart Assessment (NYHA) category classification, ECG recording for rhythm disturbance and peripheral oxygen levels by pulse oximetry (at rest).
7. QoL and depression: This will be assessed by validated tool of measuring health status, the Short Form 12 four week recall (SF-12®), a disease specific questionnaire for heart failure, the Minnesota Living With Heart Failure Questionnaire®, and the Centre for Epidemiologic Studies Depression Scale (CES-D), at baseline and at end of the study.

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Males and females aged between 18-75 yrs
2. Serum TSH between 4.01 -10.00 mU/L with normal free thyroxine levels (9 – 25 pmol/L) on two occasions (on day of admission for AMI and 7-10 days after AMI)
3. Acute myocardial infarction diagnosed on admission to hospital (chest pain with dynamic ECG changes or increase troponin enzymes (at least a fourfold increase above normal range)

Participant type


Age group




Target number of participants

Planned Sample Size: 100; UK Sample Size: 100

Total final enrolment


Participant exclusion criteria

1. Patients on medications affecting thyroid function (levothyroxine, carbimazole, propylthiouracil, amiodarone, lithium)
2. Patients who are unable to provide written informed consent
3. Patients with advanced malignancy (who, in the opinion of the investigator, is unlikely to survive for more than 6 months)
4. Patients with sustained ventricular tachycardia requiring treatment which occurs >24hrs after myocardial re-perfusion/revascularisation
5. Patients who have contra-indications to MR scanning (cardiac pacemaker, metallic heart valves, cochlear implants, coronary artery stents incompatible with MR scanning, etc.)
6. Patients who are unlikely or unwilling, in the opinion of the investigator, to attend for study specific visits
7. Participants whose serum TSH is >10.0 or <4.0 on either occasion
8. Patients who are already participating in another interventional study

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Gateshead Health NHS Foundation Trust
Department of Endocrinology
United Kingdom

Sponsor information


Gateshead Health NHS Foundation Trust

Sponsor details

Queen Elizabeth Hospital
Sheriff Hill
United Kingdom

Sponsor type

Hospital/treatment centre



Funder type


Funder name

National Institute for Health Research

Alternative name(s)


Funding Body Type

government organisation

Funding Body Subtype

National government


United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Basic results (scientific)

Publication list

1. 2015 protocol in
2. 2017 results presented at Society for Endocrinology BES 2017: DOI: 10.1530/endoabs.50.P386
3. 2020 results in (added 22/07/2020)

Publication citations

Additional files

Editorial Notes

22/07/2020: Publication reference and total final enrolment added. 29/10/2018: Publication reference added.